Share This Page
TEZSPIRE Drug Profile
✉ Email this page to a colleague
Summary for Tradename: TEZSPIRE
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for TEZSPIRE |
Recent Clinical Trials for TEZSPIRE
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Qilu Pharmaceutical Co., Ltd. | PHASE1 |
Pharmacology for TEZSPIRE
| Mechanism of Action | Thymic Stromal Lymphopoietin Blockers |
| Established Pharmacologic Class | Thymic Stromal Lymphopoietin Blocker |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for TEZSPIRE Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for TEZSPIRE Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for TEZSPIRE Derived from Patent Text Search
No patents found based on company disclosures
Tezspire Market Dynamics, Financial Trajectory, Patent Position, and Competitive Outlook
Tezspire, AstraZeneca and Amgen's tezepelumab-ekko, is one of the leading biologic growth products in severe asthma. Its commercial case rests on broad eligibility across severe asthma phenotypes, including patients without high eosinophil counts or other traditional biomarkers. Global sales have moved from launch-stage revenue to a material specialty-care franchise, but the product faces increasing competition from established biologics, expanding anti-TSLP development, payer control, and eventual biosimilar risk.
Based on public company disclosures through fiscal 2024, Tezspire's principal advantages are its upstream mechanism, broad label, and potential expansion beyond severe asthma. Its main constraints are high annual treatment cost, monthly injection administration, a crowded biologic market, and the absence of a demonstrated revenue contribution from non-asthma indications.
What is Tezspire and how does it work?
Tezspire is a human monoclonal antibody that binds thymic stromal lymphopoietin, or TSLP, an epithelial cytokine involved early in multiple inflammatory pathways. By blocking TSLP, tezepelumab acts upstream of several downstream inflammatory signals associated with severe asthma.
The FDA approved Tezspire on December 17, 2021, for add-on maintenance treatment of severe asthma in patients aged 12 years and older. The approved dose is 210 mg administered subcutaneously once every four weeks. The label does not require an elevated eosinophil count or another biomarker for treatment eligibility. [1]
What makes Tezspire different from other severe-asthma biologics?
| Product | Active ingredient | Primary target | Typical biomarker positioning | Dosing pattern |
|---|---|---|---|---|
| Tezspire | Tezepelumab-ekko | TSLP | Broad severe-asthma label | Every four weeks |
| Fasenra | Benralizumab | IL-5 receptor alpha | Eosinophilic asthma | Every four to eight weeks |
| Nucala | Mepolizumab | IL-5 | Eosinophilic asthma | Every four weeks |
| Dupixent | Dupilumab | IL-4 receptor alpha | Type 2 inflammation, including eosinophilic disease | Every two to four weeks |
| Cinqair | Reslizumab | IL-5 | Eosinophilic asthma | Intravenous, every four weeks |
| Xolair | Omalizumab | IgE | Allergic asthma | Every two to four weeks |
Tezspire's commercial positioning is strongest among patients with severe asthma who have inadequate control despite high-dose inhaled corticosteroids and additional controller therapy, but who do not fit cleanly into an eosinophilic or allergic treatment pathway.
When did Tezspire receive FDA approval and regulatory exclusivity?
The FDA approved Tezspire in December 2021 under the biologics license application pathway. The product is regulated as a biologic, so its relevant U.S. regulatory exclusivity is governed by the Biologics Price Competition and Innovation Act, or BPCIA.
| Regulatory event | Date |
|---|---|
| FDA approval | December 17, 2021 |
| Reference-product biologic exclusivity | Generally through December 2033 |
| Administration | Subcutaneous injection |
| Approved population | Patients aged 12 years and older with severe asthma |
| Dosing | 210 mg every four weeks |
| Pediatric indication | Ages 12 and older at initial approval |
The 12-year reference-product exclusivity period is separate from patent protection. A biosimilar applicant may begin certain premarket activities before the exclusivity period expires, but FDA approval cannot become effective until the statutory exclusivity period ends, subject to applicable patent litigation and settlement outcomes. [2]
Tezspire has also received regulatory approvals outside the United States, including in Europe and Japan. The timing of biosimilar entry will vary by jurisdiction because regulatory exclusivity and patent rules differ.
How large is the Tezspire market?
The addressable market is severe asthma, a smaller segment of the total asthma population but a high-cost segment with disproportionate healthcare utilization. Patients with severe asthma account for a minority of asthma cases but generate substantial spending through biologic treatment, emergency care, hospitalization, and oral corticosteroid use.
Tezspire competes in a global severe-asthma biologics market that includes:
- Dupilumab from Sanofi and Regeneron
- Fasenra from AstraZeneca
- Nucala from GSK
- Xolair from Roche and Novartis
- Cinqair from Teva
The market is expanding through greater biologic diagnosis, improved specialist access, oral-corticosteroid reduction initiatives, and treatment of patients previously classified as uncontrolled but biologic-ineligible. Tezspire's broad label gives it a potential advantage in this last segment.
What is the commercial value of Tezspire's broad label?
Tezspire does not require a biomarker threshold in its U.S. label. That expands the theoretical treatment pool beyond patients selected for eosinophilic or allergic disease.
The commercial benefit is moderated by real-world prescribing. Physicians and payers still evaluate eosinophils, immunoglobulin E, exacerbation history, oral steroid use, comorbid nasal polyps, atopic disease, and prior biologic response. In practice, Tezspire competes against products with established biomarker-driven treatment algorithms and strong physician familiarity.
The absence of a biomarker requirement is therefore a market-access advantage, not a guarantee of unrestricted use.
What is Tezspire's financial trajectory?
Tezspire has been one of AstraZeneca's faster-growing respiratory and immunology assets. Launch revenue was modest in 2022, increased materially in 2023, and continued to grow in 2024 as commercial access expanded and the product gained use in additional severe-asthma subgroups.
Public financial reporting does not always present identical revenue figures because AstraZeneca and Amgen report the collaboration through different accounting categories. AstraZeneca generally reports product sales or alliance-related revenue, while Amgen reports its economic interest through product sales, collaboration revenue, or royalty-related accounting depending on the period and reporting presentation.
Tezspire revenue trajectory
| Fiscal period | Commercial status | Financial interpretation |
|---|---|---|
| 2021 | U.S. launch in December | Minimal launch-period contribution |
| 2022 | First full commercial year | Early uptake, limited payer and physician penetration |
| 2023 | Expansion year | Strong growth as access and prescribing broadened |
| 2024 | Scale-up phase | Increasing contribution to both companies' respiratory and immunology portfolios |
| 2025 onward | Franchise-building phase | Growth depends on international penetration, severe-asthma share gains, and new indications |
A precise global revenue figure should be taken from the applicable AstraZeneca annual report and Amgen annual report because the companies' presentations are not fully interchangeable. AstraZeneca's reporting identifies Tezspire as a growth product within its respiratory and immunology portfolio. [3] Amgen also identifies tezepelumab as a commercial collaboration with AstraZeneca. [4]
What drives Tezspire revenue growth?
The main revenue drivers are:
- New patient starts among severe-asthma patients without a clear type 2 biomarker.
- Switching from other asthma biologics after inadequate control or loss of response.
- Greater use among patients with frequent exacerbations and corticosteroid dependence.
- International reimbursement and specialist adoption.
- Potential approvals in chronic rhinosinusitis with nasal polyps and other inflammatory diseases.
Revenue growth will depend more on market share and persistence than on price increases. Severe-asthma biologics are subject to payer prior authorization, step therapy, specialty-pharmacy controls, and contracting pressure.
What indications could expand Tezspire revenue?
Asthma remains the commercial foundation. AstraZeneca and Amgen have evaluated tezepelumab in other inflammatory diseases, including chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.
Chronic rhinosinusitis with nasal polyps
Chronic rhinosinusitis with nasal polyps is the most commercially logical adjacent market because:
- It overlaps with type 2 airway inflammation.
- Patients may already be managed by the same allergy, pulmonology, and otolaryngology specialists.
- Existing biologic competition validates willingness to pay for injectable targeted therapy.
- Severe asthma and nasal polyps frequently coexist.
The opportunity is also competitive. Dupilumab and omalizumab have established positions in nasal-polyp disease, and mepolizumab has an approved indication in the United States. A Tezspire label expansion would need to show clinical differentiation or provide a broader treatment profile.
Chronic obstructive pulmonary disease
COPD is a much larger potential population than severe asthma, but it is a more difficult market. Disease heterogeneity is greater, trial endpoints are complex, and biologics must demonstrate reduction in exacerbations or other clinically meaningful outcomes in a heavily genericized treatment environment.
A COPD indication could materially increase Tezspire's long-term value, but it should not be treated as part of the current base-case revenue profile without an approved label and clear phase 3 success.
What patents protect Tezspire?
Tezspire is protected by a combination of biologic regulatory exclusivity, antibody composition patents, manufacturing rights, and potentially method-of-use patents.
Unlike small-molecule drugs, Tezspire is not evaluated through the conventional small-molecule Orange Book listing framework. The relevant U.S. biologic reference product and biosimilar information is maintained through the FDA Purple Book. Patent disputes may arise under the BPCIA's patent-exchange and litigation process rather than through a conventional Hatch-Waxman Paragraph IV filing.
Is Tezspire listed in the Orange Book?
No. Tezspire is a biologic and is generally addressed through the Purple Book and BPCIA framework rather than an Orange Book product listing.
A biosimilar applicant may challenge patents identified through the BPCIA process. The absence of an Orange Book listing does not mean the product lacks patent protection.
How strong is the Tezspire patent estate?
The estate's strength depends on four elements:
| Protection layer | Strategic value |
|---|---|
| Antibody composition claims | Protect the active biologic molecule and related sequences |
| Formulation claims | Protect stability, concentration, excipients, and shelf-life characteristics |
| Manufacturing claims | Increase technical barriers to biosimilar replication |
| Method-of-use claims | Protect treatment of defined inflammatory diseases or patient populations |
The most important protection is likely the core antibody and related biologic claims. Formulation and manufacturing patents can complicate biosimilar development, but they typically provide less durable protection than a valid composition patent.
Public patent databases and regulatory records should be reviewed family by family before relying on a specific U.S. expiration date. Patent term adjustment, terminal disclaimers, continuations, and patent-term restoration can change the operative date. A single headline expiration date is not sufficient to assess Tezspire's full U.S. entry risk.
When does Tezspire lose exclusivity?
The practical U.S. biosimilar entry framework points to December 2033 as the earliest general reference-product exclusivity endpoint based on the December 2021 approval date. Actual commercial entry could occur later if relevant patents remain enforceable or if litigation produces an injunction or settlement restriction.
| Exclusivity or protection issue | Expected timing |
|---|---|
| FDA reference-product biologic exclusivity | Approximately through December 2033 |
| Core patent protection | Potentially into the early 2030s, subject to patent-family details |
| Biosimilar development activity | May begin before 2033 |
| Earliest ordinary U.S. approval effectiveness | Generally not before reference-product exclusivity ends |
| Actual generic or biosimilar competition | Dependent on patents, litigation, settlement, and manufacturing readiness |
The largest commercial risk before 2033 is therefore not ordinary biosimilar erosion. It is competitive displacement by other biologics, payer restrictions, clinical differentiation by rival products, and failure to expand into additional indications.
Are there Paragraph IV challenges to Tezspire?
Paragraph IV certifications apply primarily to small-molecule drugs regulated under the Hatch-Waxman Act. Tezspire is a biologic, so a conventional Paragraph IV challenge is not the expected legal pathway.
A biosimilar applicant would instead use the BPCIA framework. Publicly disclosed litigation involving a Tezspire biosimilar would be expected to identify the reference product, patent-exchange process, asserted patents, and any launch restrictions.
As of the public information reviewed through fiscal 2024, there was no widely reported U.S. biosimilar litigation campaign comparable to the litigation surrounding older blockbuster biologics. The absence of a public case does not eliminate future risk.
What patent litigation affects Tezspire?
No major publicly reported U.S. Tezspire patent litigation had materially altered the product's commercial timeline through fiscal 2024. The litigation profile is comparatively early because:
- FDA approval occurred in late 2021.
- The product remains within its 12-year biologic exclusivity period.
- Biosimilar manufacturers have limited commercial incentive to litigate several years before potential launch.
- The product's market is still expanding.
The litigation outlook will become more relevant as the 2033 exclusivity endpoint approaches. Potential disputes could involve antibody sequence claims, manufacturing processes, formulations, injection devices, and use in specific inflammatory diseases.
What licensing deal governs Tezspire?
Tezspire is commercialized through a collaboration between AstraZeneca and Amgen. The product originated from joint development activity involving Amgen and AstraZeneca's biologics organization, MedImmune.
The companies share development and commercialization responsibilities, with geographic and financial rights governed by their collaboration agreements. Neither company has publicly described Tezspire as a conventional third-party in-licensed product with a simple royalty-only structure. [4]
The collaboration reduces single-company development risk but also means that reported revenue and profitability must be interpreted through two corporate reporting systems. Analysts should not add AstraZeneca and Amgen figures without adjusting for intercompany accounting and revenue-sharing mechanics.
Which companies are challenging Tezspire commercially?
Dupixent
Dupixent is the most significant competitive threat because of its scale, broad immunology franchise, established asthma position, and multiple approved indications. Its physician familiarity and cross-indication use can support strong payer and specialist positioning.
Nucala and Fasenra
Nucala and Fasenra are established anti-eosinophilic biologics. They are particularly competitive in biomarker-defined patients with high eosinophil counts and recurrent exacerbations.
Xolair
Xolair remains relevant for allergic asthma and has an established safety and reimbursement history. Its dosing and administration complexity can create an opening for Tezspire in some patients, but its long commercial history supports durable physician adoption.
Emerging TSLP and upstream-pathway competitors
The success of Tezspire may encourage development of additional upstream cytokine inhibitors. New entrants could compete on dosing frequency, delivery device, biomarker breadth, efficacy, or use across asthma and other diseases.
What generic launch and biosimilar scenarios exist for Tezspire?
Base case
Tezspire retains growth through the late 2020s, reaches broader severe-asthma adoption, and enters the 2030s as a major respiratory biologic. Biosimilar competition begins around the end of the BPCIA exclusivity period, with gradual price erosion rather than immediate small-molecule-style substitution.
Upside case
A successful nasal-polyp indication or another inflammatory-disease approval expands the treated population. Tezspire becomes a multi-indication immunology product, improving persistence and commercial durability before biosimilar entry.
Downside case
Dupilumab and other competitors capture patients through broader labels, lower net pricing, stronger real-world evidence, or better administration options. Tezspire remains concentrated in severe asthma and experiences slower growth before patent and biologic exclusivity expiry.
What is the investment and revenue exposure?
Tezspire is strategically important but remains smaller than AstraZeneca's largest oncology and respiratory products. Its investment relevance comes from growth rate, margin contribution, and optionality rather than current portfolio dominance.
The main valuation variables are:
- Annual patient additions
- Net price after payer discounts
- Persistence and discontinuation rates
- Market share among biomarker-negative patients
- Expansion into nasal polyps or other indications
- Clinical differentiation against Dupixent
- Manufacturing capacity and supply reliability
- The timing and scope of biosimilar entry after 2033
A rising share of revenue from additional indications would increase franchise quality by reducing dependence on severe asthma. Continued concentration in one indication would leave the product more exposed to payer restrictions and competing biologics.
Key Takeaways
- Tezspire is a TSLP-targeting biologic approved by the FDA in December 2021 for severe asthma in patients aged 12 and older.
- Its broad, biomarker-independent label is the principal commercial differentiator.
- AstraZeneca and Amgen jointly commercialize the product.
- Revenue has moved from launch-stage sales in 2022 to material growth in 2023 and 2024.
- Dupixent, Nucala, Fasenra, and Xolair are the principal commercial competitors.
- Tezspire is a biologic and is not managed through a conventional Orange Book Paragraph IV framework.
- U.S. reference-product biologic exclusivity generally extends to approximately December 2033.
- No major publicly reported Tezspire biosimilar litigation had materially changed the commercial outlook through fiscal 2024.
- Chronic rhinosinusitis with nasal polyps is the most commercially important potential expansion market.
- The central long-term risk is competitive share loss before biosimilar erosion becomes meaningful.
FAQs About Tezspire Market and Patent Outlook
How much does Tezspire cost without insurance?
The list price for Tezspire is set by the manufacturer and may change. Actual net cost depends on insurance coverage, rebates, specialty-pharmacy arrangements, and patient assistance. Commercial access is generally controlled through prior authorization.
Is Tezspire better than Dupixent?
Neither product is universally superior. Tezspire has an upstream TSLP mechanism and a broad severe-asthma label, while Dupixent has a larger multi-indication franchise and strong positioning in type 2 inflammatory disease. Choice depends on phenotype, comorbidities, prior treatment, payer rules, and physician assessment.
Can Tezspire be used for COPD?
Tezspire is not generally approved for COPD in the United States. COPD use would require regulatory approval supported by clinical evidence.
Will Tezspire face biosimilar competition?
Yes, biosimilar competition is possible after the applicable U.S. biologic exclusivity period and patent barriers expire. The earliest ordinary U.S. timing is generally associated with the end of the 12-year reference-product exclusivity period in December 2033.
Who manufactures Tezspire?
Tezspire is developed and commercialized by AstraZeneca and Amgen. Commercial biologic manufacturing may involve internal and contracted facilities, with specific production arrangements subject to change over the product's lifecycle.
References
-
U.S. Food and Drug Administration. (2021). Tezspire prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
AstraZeneca PLC. (2025). Annual report and Form 20-F for the year ended December 31, 2024. https://www.astrazeneca.com/investor-relations/annual-reports.html
-
Amgen Inc. (2025). Annual report and Form 10-K for the year ended December 31, 2024. https://investors.amgen.com/financial-information/annual-reports-and-proxy-statements
More… ↓
